Literature DB >> 22052058

Clusterin attenuates the development of renal fibrosis.

Gwon-Soo Jung1, Mi-Kyung Kim, Yun-A Jung, Hye-Soon Kim, In-Sun Park, Bon-Hong Min, Ki-Up Lee, Jung-Guk Kim, Keun-Gyu Park, In-Kyu Lee.   

Abstract

Upregulation of clusterin occurs in several renal diseases and models of nephrotoxicity, but whether this promotes injury or is a protective reaction to injury is unknown. Here, in the mouse unilateral ureteral obstruction model, obstruction markedly increased the expression of clusterin, plasminogen activator inhibitor-1 (PAI-1), type I collagen, and fibronectin. Compared with wild-type mice, clusterin-deficient mice exhibited higher levels of PAI-1, type I collagen, and fibronectin and accelerated renal fibrosis in response to obstruction. In cultured rat tubular epithelium-like cells, adenovirus-mediated overexpression of clusterin inhibited the expression of TGF-β-stimulated PAI-1, type I collagen, and fibronectin. Clusterin inhibited TGF-β-stimulated Smad3 activity via inhibition of Smad3 phosphorylation and its nuclear translocation. Moreover, intrarenal delivery of adenovirus-expressing clusterin upregulated expression of clusterin in tubular epithelium-like cells and attenuated obstruction-induced renal fibrosis. In conclusion, clusterin attenuates renal fibrosis in obstructive nephropathy. These results suggest that upregulation of clusterin during renal injury is a protective response against the development of renal fibrosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22052058      PMCID: PMC3269926          DOI: 10.1681/ASN.2011010048

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  50 in total

1.  Clusterin protects H9c2 cardiomyocytes from oxidative stress-induced apoptosis via Akt/GSK-3β signaling pathway.

Authors:  Hyoung-Oh Jun; Dong-hun Kim; Sae-Won Lee; Hye Shin Lee; Ji Hae Seo; Jeong Hun Kim; Jin Hyoung Kim; Young Suk Yu; Bon Hong Min; Kyu-Won Kim
Journal:  Exp Mol Med       Date:  2011-01-31       Impact factor: 8.718

2.  Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.

Authors:  Bin Zhong; David A Sallman; Danielle L Gilvary; Daniele Pernazza; Eva Sahakian; Dillon Fritz; Jin Q Cheng; Ioannis Trougakos; Sheng Wei; Julie Y Djeu
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

Review 3.  Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation.

Authors:  Franck Verrecchia; Alain Mauviel
Journal:  J Invest Dermatol       Date:  2002-02       Impact factor: 8.551

4.  PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction.

Authors:  T Oda; Y O Jung; H S Kim; X Cai; J M López-Guisa; Y Ikeda; A A Eddy
Journal:  Kidney Int       Date:  2001-08       Impact factor: 10.612

5.  Clusterin is up-regulated in glomerular mesangial cells in complement-mediated injury.

Authors:  K Yamada; Y Hori; N Hanafusa; T Okuda; N Nagano; N H Choi-Miura; W G Couser; T Miyata; K Kurokawa; T Fujita; M Nangaku
Journal:  Kidney Int       Date:  2001-01       Impact factor: 10.612

6.  Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis.

Authors:  L McLaughlin; G Zhu; M Mistry; C Ley-Ebert; W D Stuart; C J Florio; P A Groen; S A Witt; T R Kimball; D P Witte; J A Harmony; B J Aronow
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

7.  Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis.

Authors:  Aihua Zhou; Hikaru Ueno; Mayumi Shimomura; Ryojiro Tanaka; Toshiro Shirakawa; Hajime Nakamura; Masafumi Matsuo; Kazumoto Iijima
Journal:  Kidney Int       Date:  2003-07       Impact factor: 10.612

Review 8.  Reactive oxygen species and matrix remodeling in diabetic kidney.

Authors:  Hunjoo Ha; Hi Bahl Lee
Journal:  J Am Soc Nephrol       Date:  2003-08       Impact factor: 10.121

Review 9.  Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up.

Authors:  Sheldon Chen; Belinda Jim; Fuad N Ziyadeh
Journal:  Semin Nephrol       Date:  2003-11       Impact factor: 5.299

Review 10.  PAI-1 as a target in kidney disease.

Authors:  Yufeng Huang; Nancy A Noble
Journal:  Curr Drug Targets       Date:  2007-09       Impact factor: 2.937

View more
  25 in total

Review 1.  Epigenetics of progression of chronic kidney disease: fact or fantasy?

Authors:  Maria R Wing; Ali Ramezani; Harindarpal S Gill; Joseph M Devaney; Dominic S Raj
Journal:  Semin Nephrol       Date:  2013-07       Impact factor: 5.299

2.  Calcium oxalate calculi-induced clusterin expression in kidney.

Authors:  Jin-Yi Li; Junjiang Liu; Junyi Jiang; Chris Pumill; Cordelia Elaiho; Yunxia Zhang; Shoubin Li; Tie Zhou
Journal:  Urolithiasis       Date:  2015-05-21       Impact factor: 3.436

3.  Clusterin negatively modulates mechanical stress-mediated ligamentum flavum hypertrophy through TGF-β1 signaling.

Authors:  Chunlei Liu; Peng Li; Xiang Ao; Zhengnan Lian; Jie Liu; Chenglong Li; Minjun Huang; Liang Wang; Zhongmin Zhang
Journal:  Exp Mol Med       Date:  2022-09-21       Impact factor: 12.153

Review 4.  The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases.

Authors:  S Park; K W Mathis; I K Lee
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

5.  Identification of the thiol isomerase-binding peptide, mastoparan, as a novel inhibitor of shear-induced transforming growth factor β1 (TGF-β1) activation.

Authors:  Teresa M Brophy; Barry S Coller; Jasimuddin Ahamed
Journal:  J Biol Chem       Date:  2013-03-05       Impact factor: 5.157

6.  Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.

Authors:  Joost P Schanstra; Petra Zürbig; Alaa Alkhalaf; Angel Argiles; Stephan J L Bakker; Joachim Beige; Henk J G Bilo; Christos Chatzikyrkou; Mohammed Dakna; Jesse Dawson; Christian Delles; Hermann Haller; Marion Haubitz; Holger Husi; Joachim Jankowski; George Jerums; Nanne Kleefstra; Tatiana Kuznetsova; David M Maahs; Jan Menne; William Mullen; Alberto Ortiz; Frederik Persson; Peter Rossing; Piero Ruggenenti; Ivan Rychlik; Andreas L Serra; Justyna Siwy; Janet Snell-Bergeon; Goce Spasovski; Jan A Staessen; Antonia Vlahou; Harald Mischak; Raymond Vanholder
Journal:  J Am Soc Nephrol       Date:  2015-01-14       Impact factor: 10.121

7.  Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling.

Authors:  Chang Joo Oh; Joon-Young Kim; Young-Keun Choi; Han-Jong Kim; Ji-Yun Jeong; Kwi-Hyun Bae; Keun-Gyu Park; In-Kyu Lee
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

8.  Clusterin/apolipoprotein J attenuates angiotensin II-induced renal fibrosis.

Authors:  Gwon-Soo Jung; Jae-Han Jeon; Yun-A Jung; Yeon-Kyung Choi; Hye-Soon Kim; Jung-Guk Kim; Keun-Gyu Park; Mi-Kyung Kim; In-Kyu Lee
Journal:  PLoS One       Date:  2014-08-22       Impact factor: 3.240

9.  Comparative transcriptional profiling of 3 murine models of SLE nephritis reveals both unique and shared regulatory networks.

Authors:  Ramalingam Bethunaickan; Celine C Berthier; Weijia Zhang; Matthias Kretzler; Anne Davidson
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

10.  Antifibrotic effects of KS370G, a caffeamide derivative, in renal ischemia-reperfusion injured mice and renal tubular epithelial cells.

Authors:  Sung-Ting Chuang; Yueh-Hsiung Kuo; Ming-Jai Su
Journal:  Sci Rep       Date:  2014-07-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.